Results 1 to 10 of about 140,447 (354)

Pharmacokinetics and safety of subcutaneous nivolumab: results from the phase I/II CheckMate 8KX study [PDF]

Journal for ImmunoTherapy of Cancer
Background CheckMate 8KX was a phase I/II study investigating the pharmacokinetics and safety of subcutaneous (SC) nivolumab±recombinant human hyaluronidase PH20 (rHuPH20).Methods Patients with advanced solid tumors who were immune-checkpoint inhibitor ...
Sara Lonardi, Christopher Jackson, R Donald Harvey, Armando Santoro, Iwona Lugowska, José Trigo, Anne O’Donnell, Richard North, Urvi Aras, Loes Maria Latten-Jansen, Linghui Li, Devanand Joseph, Bryan Bennett, Balmeet Gurm, Wee-Teck Ng, Aitana Calvo, Marcelo Garrido, Rastislav Bahleda, Matías Rodrigo Chacon, Heather E Vezina, Deepak Perumal   +20 more
doaj   +2 more sources

Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047 [PDF]

Journal for ImmunoTherapy of Cancer
Background Treatment-free survival (TFS; time spent free of systemic anticancer therapy) is increasingly used to support traditional endpoints. TFS was previously evaluated in patients with advanced melanoma treated with nivolumab plus ipilimumab.
Dirk Schadendorf, Evan J Lipson, Christopher D Lao, Hussein Tawbi, Paolo A Ascierto, David F McDermott, Michael B Atkins, Georgina V Long, F Stephen Hodi, Andriy Moshyk, Meredith M Regan, Jennell Palaia, Abraham Selvan, Ravi Potluri, Sandip Ranjan, Sandeep Bilthare   +15 more
doaj   +2 more sources

Complete remission of advanced MSI-H rectal cancer in a young patient treated with nivolumab: a case report and critical appraisal of the literature [PDF]

Front Oncol
Liberko M, Soumarova R.
europepmc   +4 more sources

Exposure‐response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040)

Clinical and Translational Science, 2023
This analysis was conducted to inform dose selection of a combination of nivolumab plus ipilimumab for the treatment of sorafenib‐experienced patients with hepatocellular carcinoma (HCC).
Bruno Sangro, Thomas Yau, Anthony B. El‐Khoueiry, Masatoshi Kudo, Yun Shen, Marina Tschaika, Amit Roy, Yan Feng, Ling Gao, Urvi Aras   +9 more
doaj   +1 more source

Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study. [PDF]

PLoS ONE, 2018
OBJECTIVES:The effectiveness of treatment after cessation of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) has not been well investigated.
Yukihiro Yano, Hiroyuki Kurebe, Ryuya Edahiro, Yuki Hosono, Saeko Nakatsubo, Kohei Nishida, Nobuyuki Sawa, Mikako Ishijima, Takeshi Uenami, Masaki Kanazu, Yuki Akazawa, Toshihiko Yamaguchi, Masahide Mori   +12 more
doaj   +1 more source

Severe lichenoid eruption due to concomitant medications following nivolumab administration

JEADV Clinical Practice, 2023
Recently, immune checkpoint inhibitors have been administered for several cancers and have shown great efficacy. However, they are associated with various immune‐related adverse events.
Risa Kakuta, Keiji Tanese, Kenro Hirata, Katsura Emoto, Sakiko Takeuchi, Chihiro Shiiya, Masayuki Amagai, Akiharu Kubo   +7 more
doaj   +1 more source

The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England [PDF]

, 2018
Background: Nivolumab was the first programmed death receptor 1 (PD-1) immune checkpoint inhibitor to demonstrate long-term survival benefit in a clinical trial setting for advanced melanoma patients.
Ellis, John, Hertel, Nadine, Johnson, Helen, Lee, Dawn, Meng, Yang, Morais, Edith, Philips, Zoe, Roskell, Neil, Walker, Andrew   +8 more
core   +1 more source

Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer

ERJ Open Research, 2018
Nivolumab for the treatment of advanced nonsmall cell lung cancer (NSCLC) evaluated in phase III trials showed 50% progression at first evaluation, but better overall survival (OS), suggesting regained efficacy of treatments given thereafter. We aimed to
Adrien Costantini, Jennifer Corny, Vincent Fallet, Sophie Renet, Sylvie Friard, Christos Chouaid, Boris Duchemann, Etienne Giroux-Leprieur, Laurent Taillade, Ludovic Doucet, Marina Nguenang, Stéphane Jouveshomme, Marie Wislez, Jean Tredaniel, Jacques Cadranel   +14 more
doaj   +1 more source

Nivolumab‐induced acute tubular injury: A case report

Clinical Case Reports, 2023
Nivolumab belongs to immune checkpoint inhibitors (ICIs). ICIs‐induced kidney injury is rare and acute interstitial nephritis (AIN) is the majority. A 58‐year‐old woman had gastric cancer treated with nivolumab.
Hui‐Hsin Yang, Chia‐Wen Chang, Tai‐Di Chen   +2 more
doaj   +1 more source

The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC [PDF]

, 2017
Background: Immune checkpoint inhibitors improve outcomes compared with chemotherapy in lung cancer. Tumor PD-L1 receptor expression is being studied as a predictive biomarker. The objective of this study was to assess the cost-effectiveness and economic
Abdel-Rahman, Aguiar, Borghaei, Brahmer, Calhoun, Chen, Dent, Domingues, Doyle, Ferlay, Goeree, Hanahan, Herbst, Herbst, Huang, Hurvitz, Masters, Matter-walstra, Moro-Sibilot, Nafees, Passiglia, Petitti, Rittmeyer, Siegel, Stokes, Tartari   +25 more
core   +3 more sources